TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

1,1200

13-марта-25 08:30:23

15 мин. задержка

Акции

+0,0100

+0,90%

Сегодняшний диапазон

1,1200 - 1,1300

ISIN

N/A

Источник

NASDAQ

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

10 мар 2025 11:40:32 Источник Nasdaq GlobeNewswire
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

07 мар 2025 15:09:46 Источник Nasdaq GlobeNewswire
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

03 мар 2025 11:52:45 Источник Nasdaq GlobeNewswire
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

28 фев 2025 12:17:46 Источник Nasdaq GlobeNewswire
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

21 фев 2025 14:28:56 Источник Nasdaq GlobeNewswire
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

14 фев 2025 17:31:40 Источник Nasdaq GlobeNewswire
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

14 фев 2025 12:16:54 Источник Nasdaq GlobeNewswire
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

14 фев 2025 10:52:04 Источник Nasdaq GlobeNewswire
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

13 фев 2025 15:34:10 Источник Nasdaq GlobeNewswire
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

10 фев 2025 16:30:20 Источник Nasdaq GlobeNewswire
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

07 фев 2025 13:56:54 Источник Nasdaq GlobeNewswire
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

28 янв 2025 14:49:48 Источник Nasdaq GlobeNewswire
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

27 янв 2025 13:24:33 Источник Nasdaq GlobeNewswire
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

24 янв 2025 16:34:26 Источник Nasdaq GlobeNewswire
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

23 янв 2025 18:53:05 Источник Nasdaq GlobeNewswire
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

26 дек 2024 11:21:56 Источник Nasdaq GlobeNewswire
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

23 дек 2024 08:38:33 Источник Nasdaq GlobeNewswire
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

19 дек 2024 07:30:00 Источник Nasdaq GlobeNewswire
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

17 дек 2024 12:32:20 Источник Nasdaq GlobeNewswire
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

10 дек 2024 14:13:52 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.